Get the Stockscreener App
13.04
2.76%
-0.37
Avita Medical Inc stock is traded at $13.04, with a volume of 318.35K.
It is down -2.76% in the last 24 hours and up +24.78% over the past month.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$13.41
Open:
$13.37
24h Volume:
318.35K
Relative Volume:
0.89
Market Cap:
$403.29M
Revenue:
$72.35M
Net Income/Loss:
$-45.34M
P/E Ratio:
-8.3031
EPS:
-1.5705
Net Cash Flow:
$-32.43M
1W Performance:
-1.29%
1M Performance:
+24.78%
6M Performance:
+161.32%
1Y Performance:
+142.38%
1-Day Range:
$12.95
$13.49
1-Week Range:
$12.80
$13.73
52-Week Range:
$3.22
$13.73
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
13.04 | 403.29M | 72.35M | -45.34M | -32.43M | -1.5705 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-26 | Upgrade | BTIG Research | Neutral → Buy |
| May-15-26 | Upgrade | Lake Street | Hold → Buy |
| Mar-05-26 | Initiated | Northland Capital | Outperform |
| Nov-20-25 | Upgrade | BTIG Research | Sell → Neutral |
| Aug-08-25 | Downgrade | BTIG Research | Neutral → Sell |
| Dec-24-24 | Initiated | D. Boral Capital | Buy |
| Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-21 | Initiated | Piper Sandler | Overweight |
| Aug-27-20 | Initiated | BofA Securities | Buy |
| Apr-21-20 | Initiated | Oppenheimer | Outperform |
| Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
Avita Medical Inc. Reports 3,994,555 Net Reduction in CDIs on Issue for September 2026 - Kalkine
Avita Medical Inc. Notifies ASX of Unquoted Option Conversions Into Common Stock - Kalkine
AVITA Medical Director Dr. Michael Tarnoff Receives RSU Vesting Into Common Stock - Kalkine
AVITA Medical Director Dr. Michael Tarnoff Converts 8,750 RSUs into Common Shares - Kalkine Media
AVITA Medical, Inc. (AVH.AX) Stock Price, News, Quote & History - Yahoo! Finance Canada
AVITA Medical (OTCPK:AVHH.L) Stock Forecast & Analyst Predictions - simplywall.st
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Avita Medical Inc. Discloses CDI and Securities Statement for August 2026 - Kalkine
Avita Medical Issues 18,293 Restricted US Stock Units to Key Management Personnel - Kalkine
Avita Medical Issues 25,213 Unquoted Options Expiring August 2036 Under Employee Incentive Scheme - Kalkine
Avita Medical Issues 17,151 Common Stock Securities Following Multiple Option Conversions - Kalkine
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat
RCEL stock gains on fresh price data while Avita Medical readies next steps - ad-hoc-news.de
Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
AVITA Medical to Present at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine
Net current asset value per share of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Investing News Network
AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine Media
A live webcast will carry AVITA Medical’s Sept. 16 conference discussion. - Stock Titan
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - TradingView
51KB Stock Price and Chart — HAM:51KB - TradingView
51KB Stock Price and Chart — HAM:51KB - TradingView
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Yahoo Finance
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - Yahoo Finance
Avita Medical Inc.ADR Peer Comparison – Compare with Others - Value Research
Avita Medical Inc.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Avita Medical Is Maintained at Buy by Lake Street - Moomoo
Avita Medical Inc.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Why Is AVITA Medical (ASX: AVH) Stock Up Over 100% in a Month? PermeaDerm Study Results Fuel the Rally - Kalkine
AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha
AVITA Medical (RCEL) CFO boosts direct stake to 152,927 shares - stocktitan.net
RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus
TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada
RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG raises Avita Medical stock price target on positive trial data - Investing.com
BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo
THREE HEALTHCARE STOCKS on radar - Kalkine
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine
AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine
AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine
Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com
AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media
AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avita Medical Inc Stock (RCEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Woody Joseph Fralin | Director |
Jun 09 '26 |
Buy |
4.19 |
10,000 |
41,900 |
102,761 |
| Woody Joseph Fralin | Director |
Jun 03 '26 |
Buy |
4.09 |
10,000 |
40,949 |
92,761 |
| Woody Joseph Fralin | Director |
Jun 02 '26 |
Buy |
4.19 |
10,000 |
41,936 |
20,000 |
| Woody Joseph Fralin | Director |
Jun 01 '26 |
Buy |
4.30 |
10,000 |
43,000 |
10,000 |
| O'Toole David D | CFO |
May 20 '26 |
Buy |
4.26 |
2,000 |
8,520 |
145,927 |
| O'Toole David D | CFO |
May 19 '26 |
Buy |
4.24 |
2,000 |
8,480 |
143,927 |
| O'Toole David D | CFO |
Feb 19 '26 |
Buy |
4.15 |
3,000 |
12,450 |
140,127 |
5.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):